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Abstract 
 
Osteoporosis has become a major public health concern, due to its rising incidence 
every year. Osteoporosis mostly occurs in women at menopause, especially in Asia. Secang 
(Caesalpinia sappan L.) heartwood contains brazilin and brazilein which are known to 
suppress expression of NF-ĸB, an osteoclastogenesis protein playing an important role in 
osteoporosis. Thus, the aim of this research is to investigate the inhibition of osteoporosis 
by ethanolic extract of secang (Caesalpinia sappan L.) (EES) in ovariectomized (OVX) rats. 
Thirty female Sprague Dawley rats were divided into five groups treated for 20 days:  group I 
were OVX and treated with 1000 mg/kgBW EES; group II were OVX and treated with 500 
mg/kgBW EES; group III were OVX and treated with CMC-Na; group IV were shame OVX 
baseline; and group V were non-OVX-baseline. Bone density was examined by using X-Ray 
rontgen and was strengthen by qualitative data of Giemsa staining. Moreover, total number 
of osteoclasts in bone slide was observed by TRAP expression using double staining 
immunohistochemistry with hematoxylin eosin (HE)–TRAP. Treatment of 500 mg/kgBW EES 
in ovariectomized rats showed the highest bone density of 0.60 gr/cm3 and the lowest 
number of osteoclasts was 4.66 osteoclasts per field of view. These results showed that EES 
is potent to be developed as an antiosteoporosis agent. Further study on its dose adjustment 
and molecular mechanism needs to be conducted.  
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INTRODUCTION 
 
Postmenopausal osteoporosis is a major 
female health problem that increases morbidity, 
mortality and healthcare system costs 
(Mendozaa, et al., 2013). Changes in body 
composition with aging and menopause, 
especially bone mass loss, have been associated 
with increased morbidity and mortality which 
predisposes to falls and osteoporosis fractures 
(Douchi, et al., 2002). Osteoporosis is 
estimated to affect 200 million women 
worldwide-approximately one-tenth of women 
aged 60, one-fifth of women aged 70, two-fifths 
of women aged 80 and two-thirds of women 
aged 90. Besides that, osteoporosis causes more 
than 8.9 million fractures annually, resulting in 
an osteoporotic fracture every 3 seconds 
(Admin International Osteoporosis Fondation, 
2013). 
 Secang (Caesalpinia sappan L.) 
heartwood has been reported as an 
antiosteoporosis agent with the important role 
of its content, flavonoids. Batubara, et al., 
2010, reported that secang heartwood contain 
flavonoid and fenolic active compound, such as 
4-0-methyl sapanol, protosappanin A, 
protosappanin B, protosappanin E, brazilin, 
brazilein, caesalpini, brazilide A, neosapanone, 
and 7,3,4-trihidroksi-3-benzil-2H. Flavonoids 
have activity to prevent osteoclastogenesis in 
NF-kB pathway (Yamamoto and Gaynor, 
2001). 
 The aim of this study is to observe 
anti-osteoporosis activity of EES in vivo. EES 
was given to the ovariectomized female 
Sprague Dawley rats as model of osteoporosis. 
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Parameters which are observed in this 
study were bone density and bone slide 
histopathology using Giemsa and TRAP 
(tartrate-resistant acid phosphatase) staining 
methods. This study is a preliminary study to 
reveal potency of secang as anti-osteoporosis 
agent. 
 
MATERIALS AND METHODS 
 
Plant Collection and Identification 
Powder of secang (Caesalpinia sappan 
L.) was obtained from B2P2TOOT, 
Tawangmangu, Central Java in February 2013 
and was identified. Powder was extracted by 
maceration for 5 days with 70% ethanol 
(E.Merck, Darmstadt, Germany). The filtrate 
was then evaporated by using vacuum rotary 
evaporator.  
 
Animals 
A total of 30 female Sprague Dawley 
rats (6 weeks), weighed from 86 to 112 g were 
purchased from Unit Pengembangan Hewan 
Percobaan Universitas Gadjah Mada. The 
animals were adapted for at least one week 
before treatment. The rats were given standard 
pellet diet and water ad libitum, with 12:12 h 
light/dark cycle. 
 
Experimental Procedure 
All animals were divided into 5 groups, 
6 rats in each group. The experimental design is 
summarized in Table 1.  Group 1 
ovariectomized (OVX)+EES 1000mg/kgBW;  
Group 2 ovariectomized (OVX)+EES 
500mg/kgBW; Group 3 ovariectomized 
(OVX)+CMC-Na as solven control; Group 4 
shame ovariectomized (OVX)+CMC-Na; and 
Group 5 non-ovariectomized (non-OVX). All 
groups were treated with EES or CMC-Na 
solution for 20 days.  
On the 22
nd
 day, all animals were 
sacrified, then left and right femur bones were 
collected. Femur bones were cleaned and 
soaked in saline 0.9%. Right femur bone was 
then fixed in 10% formalin and stained with 
TRAP and Giemsa. Left femur bone was 
examined by rontgen to determine the bone 
density. 
 
Data Analysis 
 Macroscopic analysis was done using 
X-ray rontgen  and  resulted  in bone density 
(g/cm
3
). Bone density measurement was done  
in Basic Physics Laboratory, Faculty of 
Mathematic and Natural Science, UGM. While 
microscopic analysis was done by counting 
osteoclast on bone slide stained with Giemsa 
and haematoxylin eosin (HE)-TRAP. 
 
RESULTS AND DISCUSSION 
 
Extraction and Qualitative Analysis of 
Ethanolic Extract of Secang (EES) 
Extraction process of secang by 
maceration using 70% ethanol and 51.24 gram 
of viscous extract was obtained. Yield of the 
resulting extract is equal to 10.24% w/v. 
 
Effects of EES on Bone Density  
Bone density was determined using X-
ray to compare bone density of ovariectomized 
(OVX) rats from each treatment group (Fig. 1). 
Moreover, histopathology of bone density 
matrix was also observed by using Giemsa 
staining (Fig. 2).  
The higher the density the bone matrix, 
the less the number of osteoclasts, giving a 
better bone density profile. The result of this 
study showed that ovarectomized rats (group 3) 
decreased the bone density (0.52 g/cm
3
) and 
group 2 treated with 500 mg/KgBW EES tend 
toincreased bone density (0.60 g/cm
3
). 
Moreover, group 2 has higher density than 
control (group 5) shown at (Fig. 1) based on 
both   X-ray rontgen  and   Giemsa  staining 
(Fig. 2). 
 
 
 
Table 1. Experimental Design 
Experimental group The Number of 
Female Sprague 
Dawley rats/group 
Dose Frequency 
1. OVX+EES 1000mg/kgBW 6 
Once a day for 20 days 
 
2. OVX+EES 500mg/kgBW 6 
3. OVX+CMC-Na 6 
4. Shame OVX+CMC-Na 6 
5. Non-OVX+CMC-Na 6 
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Figure 1. Effects of EES on Bone Density. Femur from each group were analyzed by using X-ray rontgen as 
described in methods. The X-ray image of femur bone of (a) Group 1 (OVX + EES 1000 mg/kgBW, (b) 
Group 2 (OVX + EES 500 mg/kgBW), (c) Group 3 (OVX), (d) Group 4 (shame-OVX), and (e) Group 5 
(control, non-OVX); (f) X-ray image the quantified to compare effect of EES on bone density. Each bar 
was mean from 6 animals. 
 
 
 
 
 
 
 
 
 
Figure 2. Histopathology of bone density matrix. The femur bone slide was stained with Giemsa to analyze 
the bone density matrix as described in the methods. Bone histopathology of (a) Group 1 (OVX + EES 
1000 mg/kgBW, (b) Group 2 (OVX + EES 500 mg/kgBW), (c) Group 3 (OVX), (d) Group 4 (shame-
OVX), (e) Group 5 (Control non OVX). Red arrows (      ) showed the bone matrix. Slide was 
observed under light microscope with 400 times magnification. 
 
 
The group treated with EES 500 
mg/KgBW showed the thickest bone matrix and 
tend to be similar to control group. Qualitative 
and quantitative bone densityshowed that 500 
mg/KgBW EES give the thickest bone density. 
These results suggest that EES increase density 
of bone matrix as seen at Fig. 1 and Fig. 2. 
 
Effects of EES on Osteoclast Formation 
Recently, it has been reported that lower 
TRAP expression reflects better bone density 
(Alatalo, et al., 2000). TRAP is secreted by 
osteoclast and and hence is used as the marker 
of osteoclasts differentiation. Osteoclast is a 
characterized cell involved in bone resorbtion. 
TRAP staining is conducted to stain the 
osteoclast. TRAP is a protein which is highly 
expressed when osteoclast differentiation 
occures. Both dose of 500 mg/kgBW EES 
(group 2) and 1000mg/kgBW EES (group 1) on 
ovariectomized rats decreased osteoclast 
formation compared to control of 
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ovariectomized rats (group 3). The osteoclast 
score of 46.30 osteoclast per field of view at 
ovariectomized rats (group 3) and 4.66 
osteoclast per field of viewat 500 mg/KgBW 
EES treated group (group 2) (Fig. 3B and 3C). 
Even, 500mg/kgBW EES gave better profile 
rather than control non-ovariectomized (group 
5) (Fig. 3B and 3E). These results suggested 
that EES 500 mg/KgBW can be developed as 
an potential anti-osteoporosis agent targetted in 
osteoclast formation inhibition. 
RANKL plays an important role in the 
differentiation and activation of osteoclasts. 
RANKL is a member of the TNF (Tumor 
Necrosis Factor) that is expressed by 
macrophages and can interact with its receptor 
(RANK) (Theill, et al., 2002). Interaction of 
RANK and RANKL can induce differentiation 
of osteoclast precursor, stimulates bone 
resorption, and maintaining mature osteoclasts. 
Continued with the activation of TRAF (TNF 
Receptor-Associated Factor) protein. TRAF6 
protein is a protein that is involved in RANK 
downstream protein signaling. TAK-1/TAB 2 
complex activates TRAF6 to activate NF-κB 
and JNK (c-jun N-terminal Kinase). NF-κB in 
the cytoplasm is inactive because of the binding 
of inhibitor protein IκB (Inhibitor of Kappa 
Light Chain Gene Enhancer in B-cells). 
Activation of NF-κB caused by the degradation 
of IκB leads to the transport of free NF-κBt into 
the nucleus that later will bind to DNA.  
The results of gene transcription 
expressing osteoclasts makethe cells can 
differentiate into mature osteoclasts (Jimi et al, 
1999). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effect of EES on osteoclast formation. Femur bone slide was stained with TRAP antibody using 
immunohistochemistry as described in the methods. Bone slide of (a) Group 1 (OVX + EES 1000 
mg/kgBW, (b) Group 2 (OVX + EES 500 mg/kgBW), (c) Group 3 (OVX), (d) Group 4 (shame-OVX), (e) 
Group 5 (Control non OVX). Red arrows (        ) showed osteoclast formation. Slide was observed 
under light microscope with 400x magnification. (f) EES treated groups gave lower number of osteoclast 
compared to OVX group. 
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Administration of EES at dose 500 
mg/KgBW to ovariectomized rats 
increasedbone density. The increase of bone 
density observed in this study was related to the 
inhibition of osteoclast formation. Based on 
previous study, EES interferes NF-κB pathway. 
Shengqian (2011) reported that EES 
significantly suppressed IL1β-mediated 
upregulation of MMP-13 mRNA and protein 
levels via abrogation of the NF-κB (p65/p50)-
driven MMP-13 promoter activation. Extract of 
Caesalpinia sappan L. shows significant 
estrogenic effect through increasing SEAP 
(Secreted Alkaline Phosphatase) activity in 
MCF-7 cells (Lai, et al., 2011). Thus, EES 
mechanism inhibiting osteoclast formation can 
be caused of NF-κB pathway alteration. 
Another pathway might be mechanism of 
EES as anti-osteoporosis agent. Beside brazilin 
and brazilein, compounds in EES perform as 
phytoestrogen, such as deoxysappanone, 
deoxysappanchalcone, and protosappanin (Lai, 
et al., 2011). Therefore, those compounds 
might perform as exogenous estrogen in post-
menopausal women. Further explorations on 
both mechanism of EES inhibiting 
osteoporosis, estrogenic effect and NF-κB 
pathway alteration, are needed to developed 
EES as anti-osteoporosis agent. 
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